HSIC — Henry Schein, Inc.

Q2 2026 revenue of $3.458B (+6.7% YoY) beat expectations, and non-GAAP EPS of $1.27 beat the $1.24 consensus while growing from $1.10 a year earlier. Management raised FY2026 guidance to 4.5%-5.5% sales growth and $5.29-$5.39 non-GAAP EPS, BTIG raised its target to $110, and the stock is just below its 52-week high. As of 2026-08-27, the tape is constructive, though Wall Street remains split between Buy and Hold rather than universally bullish.

Revenue growth has accelerated from roughly flat in early 2025 to +6.7% YoY by Q2 2026: Q1 2025 -0.1%, Q2 2025 +3.3%, Q3 2025 +5.2%, Q4 2025 +7.7%, Q1 2026 +6.3%, Q2 2026 +6.7%. Gross margin expanded to ~31.8% in Q2 2026 from ~29.4% a year earlier, helped by software mix and cost savings. GAAP EPS has been choppy but trending up, and the weak Q4 2023 print looks like an outlier rather than the current trend. This is a genuine multi-quarter acceleration, not a one-period blip.

As of 2026-08-27, trailing GAAP P/E is 26.1x versus the 5-year average of 21.5x, but that overstates cost: TTM GAAP EPS of $3.55 is depressed by amortization and restructuring charges. Using consensus FY2026 non-GAAP EPS of $5.385, the forward P/E is about 16.8x—below the 5-year average. P/S of 0.76x is also roughly in line with the 5-year average of 0.79x. On forward earnings, the stock is reasonably valued, not expensive.

The market is paying for the earnings inflection rather than the trailing GAAP line. The Q2 beat and guidance raise validated that forward narrative, which is why the stock has re-rated toward its high. If Henry Schein delivers $5.30+ non-GAAP EPS and keeps organic growth near current levels, the stock is not stretched; if cost savings slip or dental volumes soften, the forward multiple could compress back toward the mid-teens and make $90 vulnerable. Upside and downside look roughly balanced around the current quote.

As of 2026-08-27, RSI was 63.0—bullish but not overbought. Price was +1.44% above its 20-day SMA, +4.54% above its 50-day SMA, and +14.91% above its 200-day SMA. The stock sits just under the $92.18 52-week high; a clean break above that level opens room toward the low $100s, while initial support is near $86.40 (50-day), then roughly $78.60 (200-day). Momentum is intact but a bit extended short-term.

• Easing bond yields and lower financing friction support dental and medical equipment purchases by office-based practitioners.
• Cloud/software and AI workflow adoption, anchored by Dentrix Ascend with ~90% recurring revenue, is lifting mix and margins.
• Persistent dental labor shortages push practices toward Henry Schein's value-added staffing and partnership services such as GoTu.
• Commoditized consumables like gloves remain competitively priced, pressuring baseline distribution margins.
• Supply-chain cost inflation is easing, enabling the targeted $125M annualized savings run-rate by end-2026.

• Q3 2026 earnings in late October/early November 2026: evidence that organic distribution growth and the new HSLT structure are delivering.
• Cost-savings execution: reaching the $125M annualized run-rate by end-2026 and cumulative $200M+ operating income improvements.
• Continued software/cloud revenue growth and AI-enabled workflow monetization could drive further multiple expansion.

• Execution risk on restructuring and management reorganization—only early savings are visible so far.
• Dental and elective procedure volumes are cyclical; recession or continued labor shortages could slow equipment and technology demand.
• Intense competition on commoditized consumables could keep gross margin pressure alive outside software and technology.
• Balance sheet leverage: long-term debt of $2.3B versus $3.16B equity and only $157M cash leaves limited flexibility if cash flow dips or rates rise.
• The large GAAP-to-non-GAAP gap means reported earnings will lag headline non-GAAP numbers if amortization and restructuring charges persist.

Henry Schein is a stable, moderately growing healthcare distributor with an accelerating software mix, improving gross margins, and a concrete cost-savings program. At ~17x forward non-GAAP EPS as of 2026-08-27, the stock is fairly priced rather than a deep bargain: the risk/reward is balanced, modestly positive if Q3 confirms the trend, but not compelling enough to chase aggressively.

Applied an 18.2x multiple to consensus FY2026 non-GAAP EPS of $5.385—about a 15% discount to the 5-year average P/E of 21.5x to reflect low ROIC and leverage—and cross-checked against the 5-year average P/S of 0.79x on forward revenue, which gives ~$96; the two methods converge at roughly $98.00.